The goal of this observational study is to analyze the relationship between galactomannan index values and clinical outcomes , as well as to determine the annual and seasonal incidence of invasive aspergillosis in pediatric and adult patients with suspected or confirmed infection at Hospital H+ Querétaro.

The main questions it aims to answer are:

• Are high galactomannan levels significantly associated with adverse clinical outcomes, such as mortality and longer hospital stays, in immunocompromised patients?
• How does the incidence of invasive aspergillosis vary annually and seasonally between March 2022 and March 2026? Researchers will compare patients with high galactomannan levels against those with low or negative levels to see if this biomarker can be used as a reliable tool to predict patient outcomes.

The research team will:

• Collect and review clinical files of patients who had a galactomannan test from bronchoalveolar lavage samples.
• Record data on galactomannan levels, hospital stays, and patient recovery or complications.Identify risk factors and seasonal patterns of the infection.

Inclusion Criteria:

• Patients who underwent galactomannan determination testing in bronchoalveolar lavage (BAL) samples
• Tests performed during the period from March 2022 to March 2026.

Exclusion Criteria:

• Patients with galactomannan tests performed outside the established period (March 2022 to March 2026).
• Galactomannan tests performed using serum samples.

The study population comprises both pediatric and adult patients who sought medical care at Hospital H+ Querétaro and presented with either a clinical suspicion or a confirmed diagnosis of invasive aspergillosis. Participants were identified through a review of hospital clinical records, specifically including those who underwent diagnostic evaluation by means of bronchoalveolar lavage during their hospitalization.